A review on the 2-Deoxy-D-Glucose (2-DG) in COVID-19 disease
Department of Pharmacology Dr. Rajendra Gode College of Pharmacy, Malkapur, Maharashtra, India 443101.
Review Article
GSC Biological and Pharmaceutical Sciences, 2022, 19(03), 008–014.
Article DOI: 10.30574/gscbps.2022.19.3.0218
Publication history:
Received on 30 April 2022; revised on 01 June 2022; accepted on 03 June 2022
Abstract:
This has given a lead to study the role of 2-deoxy-D-glucose (2DG) against COVID-19 (corona virus) disease. We hereby would like to briefly discuss the concept and rationale behind the use of 2DG COVID-19. Virus infections can cause cell damage in many ways. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a cause of the current COVID-19 pandemic, has been extensively studied so far to investigate its pathophysiology and evaluate its impact on the metabolic system of human cells. The Drug Controller General of India (DCGI) has given emergency use approval to 2-deoxy-D-glucose (2-DG), an anti-Covid drug developed by INMAS, a DRDO lab, in collaboration with Dr Reddy's Laboratories (DRL), Hyderabad.
Keywords:
Covid; 2-deoxy-D-glucose (2DG); Corona virus; Drug Controller General of India (DCGI)
Full text article in PDF:
Copyright information:
Copyright © 2022 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
